ArticleContemporary clinical trials communications2025
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol.
Sandra Hummel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it